These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8914199)

  • 1. Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH-dependent conformational change for its biological activity.
    Sanyal G; Marquis-Omer D; Middaugh CR
    Pharm Biotechnol; 1996; 9():365-92. PubMed ID: 8914199
    [No Abstract]   [Full Text] [Related]  

  • 2. A transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein undergoes pH-dependent conformational changes conducive to membrane interaction.
    Sanyal G; Marquis-Omer D; Gress JO; Middaugh CR
    Biochemistry; 1993 Apr; 32(13):3488-97. PubMed ID: 8461310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha.
    Kihara A; Pastan I
    Bioconjug Chem; 1994; 5(6):532-8. PubMed ID: 7873657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of transferrin receptor antibody, transferrin receptor antibody bound to Pseudomonas exotoxin and transforming growth factor-alpha bound to Pseudomonas exotoxin on human tenon's capsule fibroblast proliferation.
    Smyth RJ; Kitada S; Lee DA
    J Ocul Pharmacol; 1992; 8(1):83-90. PubMed ID: 1402298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for an equilibrium intermediate in the folding-unfolding pathway of a transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein.
    Gress JO; Marquis-Omer D; Middaugh CR; Sanyal G
    Biochemistry; 1994 Mar; 33(9):2620-7. PubMed ID: 8117724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creation and anti-cancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III.
    Xiong WB; Huang N; Feng Y; Wu Q; Wang BY
    Chin Med J (Engl); 2008 Jan; 121(1):82-5. PubMed ID: 18208672
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
    J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking toxins to pieces.
    Pugsley AP
    Microbiol Sci; 1987 Oct; 4(10):312. PubMed ID: 3155273
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A.
    Collier RJ
    Cancer Treat Res; 1988; 37():25-35. PubMed ID: 2908628
    [No Abstract]   [Full Text] [Related]  

  • 11. The structure of Pseudomonas exotoxin A as a guide to rational design.
    Nicholls PJ; Youle RJ
    Targeted Diagn Ther; 1992; 7():439-46. PubMed ID: 1633305
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for the modulation of Pseudomonas aeruginosa exotoxin A-induced pore formation by membrane surface charge density.
    Rasper DM; Merrill AR
    Biochemistry; 1994 Nov; 33(44):12981-9. PubMed ID: 7947702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
    Kunwar S; Pai LH; Pastan I
    J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
    Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
    Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, function, and regulation of Pseudomonas aeruginosa exotoxin A.
    Wick MJ; Frank DW; Storey DG; Iglewski BH
    Annu Rev Microbiol; 1990; 44():335-63. PubMed ID: 2123620
    [No Abstract]   [Full Text] [Related]  

  • 16. Divergent Pseudomonas exotoxin A sensitivity in normal and transformed liver cells is correlated with low-density lipoprotein receptor-related protein expression.
    Laithwaite JE; Benn SJ; Marshall WS; FitzGerald DJ; LaMarre J
    Toxicon; 2001 Sep; 39(9):1283-90. PubMed ID: 11384715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.
    Kameyama S; Kawamata H; Pastan I; Oyasu R
    J Cancer Res Clin Oncol; 1994; 120(9):507-12. PubMed ID: 8045915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism.
    Wilson BA; Collier RJ
    Curr Top Microbiol Immunol; 1992; 175():27-41. PubMed ID: 1628498
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A.
    Gholami N; Cohan RA; Razavi A; Bigdeli R; Dashbolaghi A; Asgary V
    J Cell Physiol; 2020 Apr; 235(4):3711-3720. PubMed ID: 31578716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.